Literature DB >> 16473649

Gastrointestinal toxicity of chemotherapeutic agents.

Edith P Mitchell1.   

Abstract

Chemotherapy-induced toxicities commonly occur in sites within the gastrointestinal (GI) tract and account for dose-limiting effects. These toxicities are major contributing factors to dose reduction, delays, and cessation of cancer treatment. Through intensive therapies including surgery, combination chemotherapy, hormonal therapy, and targeted therapy, an increasing number of patients with cancer are experiencing improved survival and long-term disease-free survival, as well as palliation of disease-related symptoms. Thus, GI toxicities should be predicted and appropriate interventions initiated to prevent them when possible and provide effective supportive measures and comprehensive follow-up care. This review will discuss the etiology, incidence, prevention, and treatment of GI toxicities of cancer chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16473649     DOI: 10.1053/j.seminoncol.2005.12.001

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  24 in total

Review 1.  Microbiota in cancer development and treatment.

Authors:  Muhammad Hassan Raza; Kamni Gul; Abida Arshad; Naveeda Riaz; Usman Waheed; Abdul Rauf; Fahad Aldakheel; Shatha Alduraywish; Maqbool Ur Rehman; Muhammad Abdullah; Muhammad Arshad
Journal:  J Cancer Res Clin Oncol       Date:  2018-12-12       Impact factor: 4.553

Review 2.  Gastrointestinal symptom representation in cancer symptom clusters: a synthesis of the literature.

Authors:  Catherine H Cherwin
Journal:  Oncol Nurs Forum       Date:  2012-03       Impact factor: 2.172

3.  The efficacy and safety of the addition of olanzapine to ondansetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy.

Authors:  Veerisa Vimolchalao; Siwat Sakdejayont; Ploytuangporn Wongchanapai; Shama Sukprakun; Pattama Angspatt; Wilai Thawinwisan; Piyachut Chenaksara; Virote Sriuranpong; Chanida Vinayanuwatikun; Napa Parinyanitikun; Nattaya Poovorawan; Suebpong Tanasanvimon
Journal:  Int J Clin Oncol       Date:  2019-11-27       Impact factor: 3.402

4.  LY2228820 induces synergistic anti-cancer effects with anti-microtubule chemotherapeutic agents independent of P-glycoprotein in multidrug resistant cancer cells.

Authors:  Ronggao Chen; Yiting Qiao; Wendi Hu; Qiyang Cheng; Haiyang Xie; Lin Zhou; Xiao Xu; Shusen Zheng; Donghai Jiang
Journal:  Am J Cancer Res       Date:  2019-10-01       Impact factor: 6.166

5.  Anterior resection syndrome--a risk factor analysis.

Authors:  Cameron I Wells; Ryash Vather; Michael J J Chu; Jason P Robertson; Ian P Bissett
Journal:  J Gastrointest Surg       Date:  2014-10-18       Impact factor: 3.452

6.  Effects of 10.6-μm laser moxibustion and electroacupuncture at ST36 in a 5-Fu-induced diarrhea rat model.

Authors:  Huaijin Cheng; Ling Zhao; Ziyong Ju; Fan Wang; Meng Qin; Huijuan Mao; Xueyong Shen
Journal:  Support Care Cancer       Date:  2020-09-21       Impact factor: 3.603

Review 7.  Development of the rat model of lapatinib-induced diarrhoea.

Authors:  Joanne M Bowen
Journal:  Scientifica (Cairo)       Date:  2014-07-07

Review 8.  Chemotherapy-Induced Constipation and Diarrhea: Pathophysiology, Current and Emerging Treatments.

Authors:  Rachel M McQuade; Vanesa Stojanovska; Raquel Abalo; Joel C Bornstein; Kulmira Nurgali
Journal:  Front Pharmacol       Date:  2016-11-03       Impact factor: 5.810

9.  ACP-DA: Improving the Prediction of Anticancer Peptides Using Data Augmentation.

Authors:  Xian-Gan Chen; Wen Zhang; Xiaofei Yang; Chenhong Li; Hengling Chen
Journal:  Front Genet       Date:  2021-06-30       Impact factor: 4.599

10.  Chimonanthus nitens var. salicifolius Aqueous Extract Protects against 5-Fluorouracil Induced Gastrointestinal Mucositis in a Mouse Model.

Authors:  Zhenze Liu; Jun Xi; Sven Schröder; Weigang Wang; Tianpei Xie; Zhugang Wang; Shisan Bao; Jian Fei
Journal:  Evid Based Complement Alternat Med       Date:  2013-12-03       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.